Wegovy 7.2 mg approved in the United Kingdom
UK regulators cleared a higher-dose 7.2 mg version of Wegovy in January 2026, months before the US Food and Drug Administration approved it, giving American patients a preview of what may be coming to pharmacies this spring.
Novo Nordisk's higher-dose semaglutide injection, sold as Wegovy HD at 7.2 mg once weekly, was cleared in the United Kingdom in January 2026, ahead of European Union approval the following month. The US Food and Drug Administration approved the same drug on March 19, 2026, meaning American patients got access after UK and EU patients did [1].
The US approval was based on results from the STEP UP trial program, which tested the 7.2 mg dose against the standard 2.4 mg Wegovy dose and against placebo in about 1,400 adults with obesity. Using the measure that reflects results if people took the drug as directed, participants lost an average of 20.7% of their body weight over 72 weeks, and about one in three people, 31.2%, lost 25% or more of their starting weight [1]. A separate trial in about 500 adults with both obesity and type 2 diabetes, called STEP UP T2D, found a smaller average loss of 14.1%, with 21.3% of participants losing 20% or more [1].
When the numbers include people who did not fully stick with treatment, the results were somewhat lower: 18.7% average weight loss in the general obesity trial and 13.2% in the diabetes trial [1]. Novo Nordisk said the safety and tolerability profile of the higher dose was similar to what has been seen in earlier semaglutide trials [1].
The FDA approval came with a Commissioner's National Priority Voucher, a program meant to speed review of treatments addressing what the agency considers critical national health priorities. Novo Nordisk said this was the first GLP-1 treatment approved under that pilot program [1]. The company said it expects to launch Wegovy HD in the US in a single-dose pen in April 2026 [1].
Meanwhile, the standard-strength 7.2 mg formulation already carries approval in both the UK and EU, though Novo Nordisk said regulatory decisions on a single-dose pen version for those markets are expected in the second half of 2026 [1].
Why it matters for patients
For US patients already using Wegovy at the 2.4 mg dose, the approval of a 7.2 mg option means a stronger version could become available without switching to a different brand or molecule. The trial data suggest this dose could produce weight loss closer to what has been reported with tirzepatide-based drugs like Zepbound, though the sources here do not include a direct head-to-head comparison [1].
The gap between UK and EU approval in early 2026 and the US approval in March shows that regulatory timelines for the same drug can differ by country, even when the manufacturer is the same. Patients who read about a drug being cleared abroad should not assume it is available or approved in the US at the same time.
The safety profile was described as comparable to earlier semaglutide versions, but the sources do not detail specific side effects or how insurers might cover the higher dose, so patients weighing options may want to watch for further information from their prescribers or insurance plans.
What happens next
Novo Nordisk expects to launch Wegovy HD in the US in a single-dose pen in April 2026 [1]. Regulatory decisions on a single-dose pen version of the 7.2 mg dose in the EU and UK are expected in the second half of 2026 [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.